Other current treatments for gliomas, which included anti-VEGF (p < 0.05) or anti-c-Met (p < 0.01) antibody therapies, or TMZ (p < 0.05), also had significant decreases in tumor volumes when compared to untreated tumors. This evidence concerns the gene VEGFA and neoplasm.